Davidson Capital Management Inc. Purchases 1,279 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Davidson Capital Management Inc. increased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,672 shares of the company’s stock after acquiring an additional 1,279 shares during the quarter. Davidson Capital Management Inc.’s holdings in Medpace were worth $3,213,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. State Street Corp lifted its stake in shares of Medpace by 7.2% during the 3rd quarter. State Street Corp now owns 752,957 shares of the company’s stock worth $251,337,000 after purchasing an additional 50,312 shares during the last quarter. Geode Capital Management LLC raised its holdings in Medpace by 7.6% in the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock worth $209,885,000 after purchasing an additional 44,371 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after buying an additional 109,886 shares during the last quarter. American Capital Management Inc. boosted its holdings in shares of Medpace by 2.6% in the 3rd quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock valued at $127,060,000 after buying an additional 9,592 shares in the last quarter. Finally, FMR LLC grew its position in shares of Medpace by 11.8% in the 3rd quarter. FMR LLC now owns 231,019 shares of the company’s stock worth $77,114,000 after buying an additional 24,362 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Down 7.5 %

Medpace stock opened at $327.86 on Wednesday. The stock has a 50-day moving average price of $344.13 and a 200 day moving average price of $349.34. The company has a market capitalization of $10.19 billion, a price-to-earnings ratio of 28.71, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 17.66% and a return on equity of 50.87%. Research analysts anticipate that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on MEDP shares. Robert W. Baird increased their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. TD Cowen decreased their price target on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Finally, William Blair restated an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.